PURPOSE: We sought to estimate age-specific risk of Parkinson disease in relatives of patients with Gaucher disease, who are obligate carriers of GBA mutations and who were not ascertained by family history of Parkinson disease. METHODS: A validated family history of Parkinson disease questionnaire was administered to 119 patients with Gaucher disease who were evaluated at the Mount Sinai School of Medicine from 2009 to 2012; the ages of their parents, siblings, and children, history of Parkinson disease, age at onset of Parkinson disease, and ethnic background were obtained. Kaplan-Meier survival curves were used to estimate age-specific Parkinson disease penetrance among parents of patients with Gaucher disease, who are obligatory GBA mutation carriers. RESULTS: Two participants with Gaucher disease were affected by Parkinson disease (5.4% of those who were 60 years or older). Of the 224 informative parents of patients with Gaucher disease, 11 had Parkinson disease (4.9%). Among the parents (obligatory carriers), cumulative risk of Parkinson disease by ages 65 and 85 was estimated to be 2.2% ±2.1% and 10.9% ±7.2%, respectively. CONCLUSION: We provide useful age-specific estimates of Parkinson disease penetrance in patients with Gaucher disease and GBA heterozygous carriers for genetic counseling. Although GBA mutations may increase the risk for PD, the vast majority of patients with Gaucher disease and heterozygotes may not develop the disease. Further studies are needed to identify what modifies the risk of Parkinson disease in GBA mutation carriers.
PURPOSE: We sought to estimate age-specific risk of Parkinson disease in relatives of patients with Gaucher disease, who are obligate carriers of GBA mutations and who were not ascertained by family history of Parkinson disease. METHODS: A validated family history of Parkinson disease questionnaire was administered to 119 patients with Gaucher disease who were evaluated at the Mount Sinai School of Medicine from 2009 to 2012; the ages of their parents, siblings, and children, history of Parkinson disease, age at onset of Parkinson disease, and ethnic background were obtained. Kaplan-Meier survival curves were used to estimate age-specific Parkinson disease penetrance among parents of patients with Gaucher disease, who are obligatory GBA mutation carriers. RESULTS: Two participants with Gaucher disease were affected by Parkinson disease (5.4% of those who were 60 years or older). Of the 224 informative parents of patients with Gaucher disease, 11 had Parkinson disease (4.9%). Among the parents (obligatory carriers), cumulative risk of Parkinson disease by ages 65 and 85 was estimated to be 2.2% ±2.1% and 10.9% ±7.2%, respectively. CONCLUSION: We provide useful age-specific estimates of Parkinson disease penetrance in patients with Gaucher disease and GBA heterozygous carriers for genetic counseling. Although GBA mutations may increase the risk for PD, the vast majority of patients with Gaucher disease and heterozygotes may not develop the disease. Further studies are needed to identify what modifies the risk of Parkinson disease in GBA mutation carriers.
Authors: M Anheim; A Elbaz; S Lesage; A Durr; C Condroyer; F Viallet; P Pollak; B Bonaïti; C Bonaïti-Pellié; A Brice Journal: Neurology Date: 2012-01-25 Impact factor: 9.910
Authors: E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler Journal: N Engl J Med Date: 2009-10-22 Impact factor: 91.245
Authors: Barry Rosenbloom; Manisha Balwani; Jeff M Bronstein; Edwin Kolodny; Swati Sathe; Andrea R Gwosdow; John S Taylor; J Alexander Cole; Ari Zimran; Neal J Weinreb Journal: Blood Cells Mol Dis Date: 2010-11-10 Impact factor: 3.039
Authors: K Marder; G Levy; E D Louis; H Mejia-Santana; L Cote; H Andrews; J Harris; C Waters; B Ford; S Frucht; S Fahn; R Ottman Journal: Neurology Date: 2003-07-08 Impact factor: 9.910
Authors: Jose Bras; Coro Paisan-Ruiz; Rita Guerreiro; Maria Helena Ribeiro; Ana Morgadinho; Cristina Januario; Ellen Sidransky; Catarina Oliveira; Andrew Singleton Journal: Neurobiol Aging Date: 2007-12-21 Impact factor: 4.673
Authors: L M L de Lau; P C L M Giesbergen; M C de Rijk; A Hofman; P J Koudstaal; M M B Breteler Journal: Neurology Date: 2004-10-12 Impact factor: 9.910
Authors: Karen Marder; Gilberto Levy; Elan D Louis; Helen Mejia-Santana; Lucien Cote; Howard Andrews; Juliette Harris; Cheryl Waters; Blair Ford; Steven Frucht; Stanley Fahn; Ruth Ottman Journal: Ann Neurol Date: 2003-10 Impact factor: 10.422
Authors: Roy N Alcalay; Tama Dinur; Timothy Quinn; Karina Sakanaka; Oren Levy; Cheryl Waters; Stanley Fahn; Tsvyatko Dorovski; Wendy K Chung; Michael Pauciulo; William Nichols; Huma Q Rana; Manisha Balwani; Louise Bier; Deborah Elstein; Ari Zimran Journal: JAMA Neurol Date: 2014-06 Impact factor: 18.302
Authors: Laurie A Robak; Iris E Jansen; Jeroen van Rooij; André G Uitterlinden; Robert Kraaij; Joseph Jankovic; Peter Heutink; Joshua M Shulman Journal: Brain Date: 2017-12-01 Impact factor: 13.501
Authors: David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki Journal: Hum Genet Date: 2013-07-03 Impact factor: 4.132